Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2025.12.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Andrew Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, Zucker School of Medicine, Northwell Health, Lake Success, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Palladium, Brachytherapy, Radioisotopes. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Despite the prevalence of prostate malignancies, there remains a need to improve toxicity profiles while maintaining oncologic control. Standard whole-gland treatment prescriptions have been associated with rectal, bladder, and urethral toxicity. This dosimetric study evaluated a differential dosing approach using Pd-103 low-dose-rate brachytherapy that delivers full prescription dose (125 Gy) to MRI-visible lesions while reducing dose to uninvolved prostate tissue (100 Gy). METHODS: Twenty-seven patients with unifocal, MRI-visible, biopsy-proven low- or intermediate-risk prostate cancer were identified. For each patient, two dosimetric plans were generated: a standard plan prescribing 125 Gy to the entire prostate, and a de-escalation plan prescribing 125 Gy to the MRI-visible lesion and 100 Gy to the remaining prostate. Dosimetric parameters including rectal D0.1cc and D2cc, bladder D2cc and D10cc, and urethral D10% and D30% were compared using Wilcoxon signed-rank tests. RESULTS: Fifty-four plans (27 standard, 27 de-escalation) were analyzed. The de-escalation approach achieved statistically significant dose reductions to all organs at risk (p 20%). While these dosimetric improvements suggest potential for reduced toxicity, clinical validation through our ongoing prospective Phase II trial is needed to confirm clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Medicine, Zucker School of Medicine, Northwell Health, Lake Success, New York, NY.
- Biostatistics Unit, Office of Academic Affairs, Northwell Health, New Hyde Park, New York, NY.
- Department of Radiation Medicine, Zucker School of Medicine, Northwell Health, Lake Success, New York, NY. Electronic address: bparashar@northwell.edu.
Zitieren
APA
Xue, A., Wang, L., Akerman, M., Gogineni, A., Coelho, A., Potters, L., & Parashar, B. (2026). Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.12.010
Vancouver
Xue A, Wang L, Akerman M, Gogineni A, Coelho A, Potters L, et al. Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.12.010
BibTeX
@article{Xue2026,
author = {Xue, Andrew and Wang, Lin and Akerman, Meredith and Gogineni, Aarush and Coelho, Anthony and Potters, Louis and Parashar, Bhupesh},
title = {Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2025.12.010}
}
EUVIMED